摘要
目的通过前瞻性随机对比研究,评价华法林低强度抗凝预防非瓣膜性房颤发生血栓栓塞的有效性和安全性。方法将102例持续性房颤病人分为华法林低强度抗凝观察组及华法林标准强度抗凝对照组。观察组抗凝目标值INR1.5～2.0,对照组抗凝目标值INR2.1～3.0。常规门诊随访,检测INR调整华法林剂量,并记录两组病人的终点事件及出血事件。结果随访3年,低强度抗凝与标准强度抗凝相比,血栓栓塞事件的发生率无显著差别,而出血并发症低强度抗凝组明显低于标准强度对照组(0.0%vs14%,P<0.01)。结论华法林低强度抗凝(INR1.5～2.0)预防非瓣膜性房颤发生血栓栓塞并发症是安全有效的。
Objective To evaluate the safety and efficacy of low intensity anticoagulation therapy with warfarin for the prevention of thromboembolism in nonvalvular atrial fibrillation. Methods 102 patients with persistent nonvalvular atrial fibrillation were randomly divided into low intensity anticoagulation therapy with warfarin group （ INR 1.5 - 2.0） and standard intensity anticoagulation therapy with warfarin group （ INR 2.1 -3.0）. The dose of warfarin was adjusted according to INR. Both ischemic and major hemorrhagic events were compared during follow-up three years. Results There was no significant difference of the thromboembolism event between the two groups. All the bleeding events in low intensity anticoagulation with warfarin group was significantly lower than that in standard intensity anticoagulation group（ 0.0% vs 14% ,P 〈 0.01 ）. Conclusion Low intensity anticoagulation therapy with warfarin is effective and safe for prevention ischemic stroke in patients with nonvalvular atrial fibrillation.
出处
《血栓与止血学》
2010年第2期61-62,共2页
Chinese Journal of Thrombosis and Hemostasis
基金
广东省科技基金资助项目(编号:200713060401041)
关键词
心房颤动
血栓栓塞
华法林
Atrial fibrillation
Thromboembolism
Warfarin
